Abstract 4820: Anti-CD72 nanobody-based CAR-T affinity maturation leads to improved in vitro efficacy versus low antigen density lymphoma models, but limited benefit in vivo
Adila Izgutdina(University of California, San Francisco), Arun P. Wiita(University of California, San Francisco), Huimin Geng(University of California, San Francisco), Akul Naik(University of California, San Francisco), Bonell Patiño-Escobar(University of California, San Francisco), Szu-Ying Chen(University of California, San Francisco), Nirali N. Shah(National Institutes of Health), Veronica Steri(University of California, San Francisco), Haley Johnson(University of California, San Francisco), Samir Parekh(The Ohio State University Wexner Medical Center), Fernando Salangsang(Novartis (Switzerland)), Paul Phojanakong(UCSF Helen Diller Family Comprehensive Cancer Center), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Amrik S. Kang(University of California, San Francisco), Sarah Aminov(Albert Einstein College of Medicine), Christopher Carpenter(Beaumont Hospital, Royal Oak), Emilio Ramos(University of California, San Francisco), Juan A. Cámara(UCSF Helen Diller Family Comprehensive Cancer Center), Matthew A. Nix(University of California, San Francisco), Daniel Gil-Alós(University of California, San Francisco), Isa Tariq(UCSF Helen Diller Family Comprehensive Cancer Center), Hao‐Wei Wang(Fu Jen Catholic University), Amit Verma(M.J.P. Rohilkhand University), Srabani Sahu(Albert Einstein College of Medicine), Tasfia Rashid(University of California, San Francisco), Antonio Valeri(Research Institute Hospital 12 de Octubre), H Takamatsu(Kanazawa University), Constance M. Yuan(National Cancer Institute), Sujata Walunj(University of California, San Francisco), William C. Temple(UCSF Benioff Children's Hospital)
Cited by 1
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
|Nature Medicine|2015|1.4k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
|Genes & Development|2010|744